Abstract: A peptide comprising the sequence VKVKVRVKVDPPTKVKVRVKV-NH2 forms a hydrogel which has the ability to shear-thin and recover. The hydrogel, both before and after shear-thinning, is capable of killing bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Abstract: Several bacterial species were isolated from marine segment obtained from seabed sediment at depths exceeding 1700 feet. At least four of the bacteria produced a compound that showed antibacterial activity against one or more multiple-drug-resistant (MDR) bacteria isolated from hospitals and clinics. One isolate, SJCH-12, exhibited a broad range of activity against MDR strains tested, including methicillin resistant Staphylococcus aureus (MRSA).

Abstract: Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues are administered as modified peptides, preferably containing photo-oxidized solubilizer.

Abstract: The present invention involves the use of activators of bacterial agr quoroum-sensing systems to block, inhibit or reverse biofilm formation. The biofilm may be located on an industrial or medical surface, or may be located in a subject, such as in a wound or infected organ, or on an in-dwelling medical device.

Abstract: Disclosed herein are methods and compositions related to GHS-R antagonists.

Abstract: The present invention relates to methods for treating infective endocarditis, such as bacterial endocarditis, with defensin polypeptides.

Abstract: Methods and compositions for treating microbial infections associated with an emergence of resistance of a pathogenic microorganism to an antimicrobial agent, following treatment with antimicrobial agent are disclosed. The methods are effected by using a polymer which exhibits antimicrobial re-sensitizing activity, for re-sensitizing the pathogenic microorganisms to the antimicrobial agent, in combination with the antimicrobial agent. Further disclosed are novel polymers having an antimicrobial re-sensitizing activity.

Abstract: Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR polypeptide or peptide or fragment or derivative or analog thereof to the individual.

Abstract: The present invention provides antibacterial peptides isolated from lactobacillus GG. Also provided are methods of treating an individual having a bacterial infection or at risk for developing a bacterial infection, comprising the steps of administering an antibacterial peptide of the invention to an individual having a bacterial infection or at risk for developing a bacterial infection.

Abstract: The present invention discloses certain derivatives of artemisinin and the active principles contained in Artemisia annua extracts with amino acids, peptides, and amino sugars, and isomers and salts thereof (formula I).

Abstract: With a microorganism-inactivating agent comprising a composition containing ?-polyglutamic acid and/or cross-linked product of ?-polyglutamic acid; a calcium ion donor; a sodium ion donor; and an aluminum ion donor, microorganisms in water are inactivated. By further including one or more selected from microbiostatic agents and microbicides into the microorganism-inactivating agent, various microorganisms in water are inactivated to a level at which the water is suitable for drinking.

Abstract: Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections. Certain peptides are disclosed utilizing a structure-based rational modification of antimicrobial peptide D1, with single D-/L-amino acid substitutions or charged residue substitutions in or near the center of the peptide on the nonpolar or polar face, or peptides with one or more amino acids in the D configuration, and peptides with all amino acids in the D configuration. Modified peptide analogs herein can demonstrate one or more properties such as improved antimicrobial activity, specificity, and resistance to degradation.

Abstract: The present invention relates to peptides comprising amino acids according to Formula I ((X)l(Y)m)n??(I) wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, together with methods for the use of the peptides in the treatment of microbial infections.

Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.

Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.

Abstract: Antimicrobial peptides of the formula are provided: X1—X2—PrO—X3—X4—PrO-Arg-Pro-Tyr-Leu-Pro-X5-Pro-Arg-Pro-Pro-Arg-Pro-Y, wherein X1 is a natural or non-natural amino acid having a free amino group or 1-amino-cyclohexyl carboxylic acid, X2 is Arg or N-methyl-Arg, X3 is Asp or GIu, X4 is Arg or Lys, X5 is Arg or Lys, and Y is Arg, Arg-NH2, N-methyl-Arg, N-methyl-Arg-NH2, Val-Arg, Val-Arg-NH2, Val-(N-methyl-Arg), or Val-(N-methyl)-Arg-NH2, and salts thereof.

Abstract: The invention provides an immunogenic molecular entity, a supramolecular assembly, and an antibody that can be used to inhibit Gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a Gram-positive bacterial infection. The invention also provides methods of inhibiting Gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a Gram-positive bacterial infection.

Abstract: The present invention provides actagardine, actagradine B and deoxy actagardine B derivatives of formula (I), wherein: X1 denotes that the residue is Leu; Val; or Ile; X2 denotes that the residue is Leu; Val; or Ile; R1 represents an alkyl or heteroalkyl group, substituted by at least one hydroxyl substituent, and R2 represents hydrogen, or an alkyl or heteroalkyl group, optionally substituted by at least one hydroxyl substituent, or R1 and R2 taken together with the nitrogen atom represent a heterocyclic group having at least one hydroxyl substituent, wherein the heterocyclic group optionally further contains one or more heteroatoms; Z is an amino acid residue, —NR3R4, —NR5COR6, —NR5C(O)OR6; —NR5SOR6, NR5SO2R6; —NR5C(S)NR6R7, —NR5C(NR8)NR6R7, or —N?R9, where R3, R4, R5, R6, R7, R8 and R9 are independently hydrogen, or a group, optionally substituted, selected from alkyl, heteroalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl, with the proviso that R9 is not hydrogen; and Y is —S— or —S(O)—.

Abstract: The present invention relates to compositions for removing a biofilm formed by Staphylococcus aureus, comprising a bacteriophage, such as Myoviridae family T4-like phage genus bacteriophage (Accession No: KCTC 11153BP, SAP-I) or Podoviridae family ?29-like virus genus bacteriophage (Accession No: KCTC11154BP, SAP-2), and lytic protein derived therefrom, that destroys the biofilm. Also disclosed are pharmaceutical compositions for the treatment of diseases caused by Staphylococcus aureus capable of forming biofilm.

Abstract: The invention relates to compositions comprising a compound based on the general formula (I) R1-Arg-R2—NH—CH(R3)—CH2—NH—R4??(I) The composition may be used to eliminate and/or reduce microorganisms such as bacteria, viruses, fungi and protozoa.